SANTA CLARA, Calif., June 18 /PRNewswire-FirstCall/ --
Applied Imaging Corp. (Nasdaq: AICX) announced today the formation of a
Scientific Advisory Board to provide advice and direction in scientific
research and product development for its OncoPath(TM) image analysis systems.
The Board is comprised of academics and medical professionals representing
a wide range of research and clinical interests in the field of cancer and
pathology. As a result, the Company believes it has assembled a distinguished
international membership with a deep understanding of clinical trends, which
will be instrumental in identifying new applications for its OncoPath systems.
Applied Imaging's OncoPath systems (Ariol(TM), MDS(TM) and SPOT(TM)) provide
advanced scanning microscopy capabilities that detect targeted cancer cells in
concentrations as low as one cell among one million other cells. Once
detected, the systems utilize proprietary analysis software for the
characterization of both genes and proteins in these cells.
"We are delighted to welcome these distinguished scientists to our new
Scientific Advisory Board," said Carl Hull, President and Chief Executive
Officer of Applied Imaging. "The formation of the Board is another step
towards executing our stated strategy of expanding the capabilities and
applications of our OncoPath systems. We expect that the Board will provide us
with powerful insights into new clinical and research opportunities for our
technologies in the oncology and pathology markets. In particular, the members
of the advisory board will be invaluable in helping us recognize emerging
analytical needs that can be met by our Ariol system."
The membership of the board includes:
-- John Bartlett PhD, Head of the Endocrine Research Group and Senior
Lecturer at the University of Glasgow in the United Kingdom
-- Lyndsay Harris MD, Assistant Professor, Department of Medicine,
Harvard Medical School; Medical Oncology/Solid Tumor Oncology,
Breast and Gynecological Cancer at the Dana-Farber/Harvard Cancer
Center, Boston, USA
-- Michael Press MD, PhD, Professor, Department of Pathology and holding
the Harold E. Lee Chair in Cancer Research in the USC/Norris Cancer
Center, Los Angeles, USA
-- David Seligson MD, Assistant Professor, Department of Pathology &
Laboratory Medicine; Director of the UCLA Tissue Array Core Facility;
and member of the Jonsson Comprehensive Cancer Center at the University
of California at Los Angeles, USA
-- Hans Tanke PhD, Professor & Head of the Department of Molecular Cell
Biology of the Leiden University Medical Center, Leiden,
The Netherlands
The activities of the board will be coordinated by Duncan Borthwick, PhD,
of Applied Imaging.
About Applied Imaging
Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories throughout the world for the analysis of chromosomes in cancer
and prenatal disorders. The Company markets a range of imaging systems for
fluorescence and brightfield microscopy applications, including the Company's
Ariol(TM), MDS(TM), SPOT(TM), CytoVision(R), PowerGene(R) and QUIPS(R) product
lines. Applied Imaging has installed in excess of 3,000 systems in over
1,000 laboratories in more than 60 countries.
This press release contains forward looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding the potential
benefits that may result from establishment of the scientific advisory board
announced in this Press Release. Forward looking statements address matters
that are subject to a number of risks and uncertainties, including the
Company's ability to identify new market opportunities and develop new
applications for its OncoPath systems. Further information on potential risk
factors that could affect the Company, its business and its forecasts are
detailed in the Company's periodic filings with the Securities and Exchange
Commission, including, but not limited to, those risks and uncertainties
listed in the section entitled "Management's Discussion and Analysis of
Financial Condition and Results of Operations -- Factors Affecting Future
Results," in Applied Imaging's annual report on Form 10-K for the year ended
December 31, 2002, filed with the Securities and Exchange Commission. The
forward-looking statements are made as of June 18, 2003 and Applied Imaging is
under no obligation to revise or update the forward-looking statements.
For additional information on Applied Imaging, visit the Company's Web
site at http://www.aicorp.com .
SOURCE Applied Imaging Corp.
 back to top
Related links:
http://www.aicorp.com
CONTACT:
Barry Hotchkies, CFO of Applied Imaging
Corp., +1-408-562-0250; or James Hoyne of FRB/Weber Shandwick,
+1-310-407-6546, for Applied Imaging Corp.
|
